Gossamer Bio, Inc. (GOSS) Key Metrics
GOSS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $53.6M
- Enterprise value
- $50.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.0
- Price / book
- 2.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.21
GOSS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGOSS valuation Price multiples at each fiscal year-end price.
GOSS returns How much profit the business earns on the capital it uses.
GOSS per-share figures Results divided by the shares outstanding at year-end.
GOSS financial health Debt, liquidity and how easily interest is covered.
GOSS efficiency & capital use Working capital cycle and where the cash goes.
GOSS valuation history
GOSS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GOSS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GOSS price vs earnings per share
GOSS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $708.4M | $204.7M | $139.3M | — | — | — | — | — | — | — |
| Enterprise value | $774.4M | $113.1M | $55.4M | — | — | — | — | — | — | — |
| Price / sales | 14.6 | 1.8 | — | — | — | — | — | — | — | — |
| Price / book | — | 6.9 | 2.2 | — | — | — | — | — | — | — |
| EV / sales | 16.0 | 1.0 | — | — | — | — | — | — | — | — |
| Earnings yield | −24.0% | −27.6% | −129.0% | — | — | — | — | — | — | — |
| Free cash flow yield | −24.2% | −1.7% | −114.2% | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $248.00 | $72.40 | $73.04 | $173.60 | $904.80 | $773.60 | $1,250.40 | — | — | — |
| Per share | ||||||||||
| Revenue per share | $16.97 | $40.56 | $0.00 | — | — | — | — | — | — | — |
| Earnings per share | −$59.64 | −$19.99 | −$94.26 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$59.96 | −$1.23 | −$83.43 | — | — | — | — | — | — | — |
| Free cash flow per share | −$59.98 | −$1.23 | −$83.43 | — | — | — | — | — | — | — |
| Cash per share | $47.94 | $104.15 | $155.38 | — | — | — | — | — | — | — |
| Book value per share | −$42.98 | $10.43 | $32.90 | — | — | — | — | — | — | — |
| Tangible book value per share | −$42.98 | $10.43 | $32.90 | — | — | — | — | — | — | — |
| Capex per share | $0.03 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Debt per share | $71.03 | $71.74 | $111.37 | — | — | — | — | — | — | — |
| Shares outstanding | 2.9M | 2.8M | 1.9M | — | — | — | — | — | — | — |
| Change in shares outstanding | +1.0% | +48.2% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −122.5% | −480.5% | −343.5% | −105.8% | −72.3% | −155.6% | — | — | — |
| Return on assets (ROA) | −69.9% | −18.0% | −61.5% | −74.5% | −53.0% | −50.4% | −54.3% | −122.5% | — | −138.3% |
| Return on tangible assets | −98.9% | −17.9% | −57.6% | −84.2% | −68.1% | −45.1% | −42.4% | −61.4% | — | −138.3% |
| Free cash flow margin | −353.5% | −3.0% | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $202.9M | $202.9M | $212.5M | $225.7M | $185.2M | $183.7M | $39.5M | — | $6.0M | $40,000 |
| Cash & short-term investments | $136.9M | $294.5M | $296.4M | $255.7M | $325.2M | $512.6M | $401.8M | $228.7M | $315,000 | $60,000 |
| Net debt | $66.0M | −$91.6M | −$84.0M | −$29.9M | −$140.0M | −$328.9M | −$362.2M | −$228.7M | $5.7M | −$20,000 |
| Debt / equity | — | 6.88 | 3.38 | 18.69 | 1.53 | 0.57 | 0.11 | — | — | — |
| Debt / assets | 1.18 | 0.64 | 0.68 | 0.83 | 0.54 | 0.34 | 0.09 | — | 13.57 | 0.67 |
| Current ratio | 2.64 | 6.88 | 5.94 | 5.32 | 8.32 | 13.51 | 11.09 | 11.37 | 0.35 | 0.42 |
| Quick ratio | 2.64 | 6.88 | 5.94 | 5.32 | 8.33 | 13.50 | 11.13 | 11.37 | 0.35 | 0.42 |
| Interest coverage | -14.9 | -5.2 | -13.6 | -15.7 | -11.1 | -16.6 | — | — | -56.4 | — |
| Working capital | $104.2M | $264.9M | $254.9M | $212.7M | $291.9M | $483.7M | $372.4M | $211.6M | −$821,000 | −$83,000 |
| Invested capital | −$56.8M | −$62.1M | −$21.2M | −$17.9M | −$18.5M | −$8.2M | −$9.7M | −$348.7M | −$1.1M | −$143,000 |
| Tangible asset value | −$122.8M | $29.5M | $62.8M | $12.1M | $121.5M | $320.7M | $352.5M | −$120.1M | −$6.9M | −$123,000 |
| Net current asset value | −$127.4M | $24.1M | $57.4M | $1.5M | $109.6M | $303.6M | $335.2M | −$127.5M | −$6.9M | −$123,000 |
| Graham net-net per share | −$52.05 | $4.50 | $24.78 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Capex / revenue | 0.2% | 0.0% | — | — | — | — | — | — | — | — |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | — | 17,450.0% |
| Capex / depreciation | 0.08 | 0.00 | 0.00 | 0.11 | 0.31 | 5.83 | 2.13 | 71.42 | 3.03 | 42.05 |
| Stock-based compensation / revenue | 21.8% | 18.0% | — | — | — | — | — | — | — | — |
| R&D / revenue | 359.2% | 120.7% | — | — | — | — | — | — | — | — |
| SG&A / revenue | 77.6% | 31.5% | — | — | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 67.3 | 17.0 | — | — | — | — | — | — | — | — |
| Days of inventory on hand | — | — | — | — | 8.1 | -48.5 | -177.2 | — | — | — |
| Days payables outstanding | 1,507.7 | 344.9 | 290.7 | 193.8 | 379.8 | 361.9 | 185.4 | 1,400.4 | — | — |
| Cash conversion cycle (days) | -1,440.5 | -327.9 | — | — | — | — | — | — | — | — |
| Receivables turnover | 5.43 | 21.49 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Payables turnover | 0.24 | 1.06 | 1.26 | 1.88 | 0.96 | 1.01 | 1.97 | 0.26 | 0.00 | 0.00 |
| Asset turnover | 0.20 | 0.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $8.9M | $5.3M | — | — | $200,000 | $850,000 | $1.0M | $500,000 | — | — |
| Average payables | $4.1M | $3.9M | $3.5M | $2.4M | $5.4M | $4.2M | $1.6M | $1.1M | $68,500 | $40,000 |
| Average inventory | — | — | — | — | $114,500 | −$567,500 | −$1.5M | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from GOSS's annual financial statements (latest annual report filed March 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GOSS valuation and financial ratios
It ended the year with $202.9 million of debt and $136.9 million in cash and short-term investments, net debt of $66.0 million.
See the GOSS income statement, the GOSS chart for price history, or the GOSS stock overview for the latest quote and news.
GOSS key metrics FAQ
How much debt does Gossamer Bio have?
Gossamer Bio had total debt of $202.9 million at the end of fiscal 2025.
What is Gossamer Bio's free cash flow yield?
Gossamer Bio generated -$171.3 million of free cash flow in fiscal 2025, a free cash flow yield of −24.2% on its market value at year-end ($708.4 million).
What is Gossamer Bio's current ratio?
Gossamer Bio's current ratio was 2.64 at the end of fiscal 2025: current assets were 2.64 times current liabilities.